Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 86 of 6351
-
Can a Ready-Made mRNA vaccine train the immune system to fight many cancers?
Disease control Recruiting nowThe purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Aug 23, 2026 20:09 UTC
-
Can a smarter surgery and antibiotic combo cure joint infections for good?
Cure Recruiting nowArtificial joint infections are treated with different types of antibiotics and surgery. The ROADMAP study aims to find out which treatments currently used work best in regards to surgery, antibiotic choice as well as the time taking antibiotics. The study will compare different …
Phase 4 • Sponsor: University of Newcastle, Australia • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Could your own lung cells heal COPD? a new stem cell trial aims to find out
Disease control Recruiting nowThis clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and imp…
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
CRISPR gene editing offers hope for sickle cell patients
Disease control Recruiting nowThis study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and he…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for aggressive breast cancer: targeted drug combo shows promise in early trial
Disease control Recruiting nowResearchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New malaria vaccine trial aims to protect women and their future babies
Vaccine OngoingThis will be a double-blind, individually randomised trial, to assess the safety, tolerability, immunogenicity, and protective efficacy of two and three doses of the R21/Matrix-M1 malaria vaccine or placebo given at 4 week intervals in healthy women of childbearing potential (WOC…
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 09:08 UTC
-
New hope for Crohn's: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Brain cancer vaccine shows promise in new trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell i…
Phase 2 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for aggressive breast cancer: drug combo trial launches
Disease control Recruiting nowResearchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can Clot-Busters overcome blood thinners to save brains?
Disease control Recruiting nowDO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute ischemic stroke (AIS) with recent (within the last …
Phase 4 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could stroke patients on blood thinners finally get clot-busting treatment?
Disease control Recruiting nowThis study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors…
Phase 3 • Sponsor: Guri Hagberg • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat multiple myeloma
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Phase 3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo aims to beat back relapsed leukemia
Disease control Recruiting nowThis pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.
Phase 2/3 • Sponsor: Moleculin Biotech, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a cell cocktail stop type 1 diabetes before it starts?
Disease control Recruiting nowThe main purpose of the study is to check: * Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or delay type 1 diabetes? * Is therapy with a prep…
Phase 2 • Sponsor: PolTREG S.A. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a pill replace injections to fight advanced prostate cancer?
Disease control CompletedThe purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can radiation beads shrink untreatable liver tumors?
Disease control Recruiting nowAt four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment respon…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a brief ER talk save young lives? major study tests two suicide prevention strategies
Symptom relief Recruiting nowThe study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Stem cell eye treatment could restore sight in retinal disease patients
Disease control Recruiting nowStudy OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and featur…
Phase 1/2 • Sponsor: BlueRock Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Engineered immune cells take aim at hard-to-treat blood cancers
Cure Recruiting nowThis is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lin…
Phase 1 • Sponsor: GC Cell Corporation • Aim: Cure
Last updated Jul 26, 2026 00:00 UTC
-
Can engineered immune cells tame a debilitating autoimmune disease?
Disease control Recruiting nowThis study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020 injection in the participants with refractory systemic myasthenia gravis, and determine the recommended…
Phase 1 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC